← Eichor
Study identifier: NCT06699420 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Qishenyiqi Dripping Pill for Coronary Microvascular Disease

Condition: Coronary Microvascular Disease  ·  Sponsor: Qilu Hospital of Shandong University

PhasePhase 4
Planned participants162
Who can joinAll sexes, 40 Years to 75 Years
Healthy volunteersNo

About this study

To investigate the efficacy and safety of Qishenyiqi in patients with microvascular angina pectoris. Long-term follow-up of 1 year will be performed to evaluate the effect of Qishenyiqi on coronary flow reserve and adverse cardiovascular events in patients with coronary microvascular disease.

This description comes directly from the study's public registry record.

Talk to the study team

Panpan Hao, Dr.  ·  8618560086593  ·  panda.how@sdu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (3)

Qianfoshan Hospital, Shandong UniversityJinan, Shandong, ChinaActive Not Recruiting
Qilu Hospital of Shandong UniversityJinan, Shandong, ChinaRecruiting
Jinan Central Hospital Affiliated to Shandong First Medical UniversityJinan, Shandong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06699420